Bayer warns of increasing competition
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BAYER, the German chemical and pharmaceutical group, yesterday signalled increased competition in the industry and said it expected a fall in profits for 1992, writes Heather Connon.
The group warned that there was no sign of recovery in its markets and said it expected no fundamental improvement in the second half. 'We are bracing ourselves for tougher competition in all areas,' the group said.
The warning came as Bayer announced a 9.8 per cent fall in pre- tax income to DM1.7bn ( pounds 626m) in the first half, on sales static at DM22.2bn. Earnings in Germany fell 13.7 per cent to DM967m as pressure on prices continued.
Meanwhile, Rhone Poulenc, the French chemical and healthcare group, reported a 22 per cent rise in operating income to Ffr4bn ( pounds 420m) in the six months to June. The advance was largely due to its healthcare business, where operating income rose a third to Ffr2.15bn.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments